Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 17 - Drugs for dermatological disorders
Patents for A61P 17 - Drugs for dermatological disorders (106,455)
10/2001
10/11/2001WO2001021587A3 Hydroxyfunctional amide 1h-indole derivatives active as spla2 inhibitors
10/11/2001WO2001021141A3 Personal-care compositions
10/11/2001WO2001012264A3 Topical azathioprine for the treatment of oral autoimmune diseases
10/11/2001WO2001007470A3 Human nervous system-associated proteins
10/11/2001US20010029266 Skin disorders, mucous membranes, keratin fibers
10/11/2001US20010029263 Alopecia
10/11/2001US20010029253 Composition for external application containing a beta-1,6-branched-beta-1,3-glucan
10/11/2001US20010028893 Pressurization
10/11/2001US20010028889 Topical
10/11/2001US20010028888 Cosmetic or dermatological light protection agent preparations
10/11/2001CA2404896A1 Human ion channel protein and polynucleotides encoding the same
10/11/2001CA2404592A1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
10/11/2001CA2404484A1 Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis
10/11/2001CA2404413A1 Small organic molecule regulators of cell proliferation
10/11/2001CA2404384A1 Substituted 1,3-thiazole compounds, their production and use
10/11/2001CA2404376A1 O-glucosylated benzamide sglt2 inhibitors and method
10/11/2001CA2404373A1 O-aryl glucoside sglt2 inhibitors and method
10/11/2001CA2404300A1 Medical devices suitable for gene therapy regimens
10/11/2001CA2404074A1 Human polynucleotides, polypeptides, and antibodies
10/11/2001CA2403885A1 Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist
10/11/2001CA2402078A1 Divided dose therapies with vascular damaging activity
10/11/2001CA2401948A1 Cd20/ige-receptor like molecules and uses thereof
10/11/2001CA2401888A1 Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
10/11/2001CA2401854A1 Therapeutic combinations of antihypertensive and antiangiogenic agents
10/11/2001CA2401269A1 Compositions and methods for treating hair loss using oximyl- and hydroxylamino- prostaglandins
10/11/2001CA2399275A1 Novel benzosultam oxazolidinone antibacterial agents
10/10/2001EP1142890A1 Aminopyrazole derivatives
10/10/2001EP1142889A1 Pyrazole derivatives as anti-inflammatory/analgesic agents
10/10/2001EP1142581A2 Tissue sealant and growth factor containing compositions that promote accelerated wound healing
10/10/2001EP1142575A1 Dry skin remedies
10/10/2001EP1141728A1 Kidney disease detection and treatment
10/10/2001EP1141342A2 Use of plus-strand synthesis elements in retroviral vectors
10/10/2001EP1141339A1 Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
10/10/2001EP1141332A1 Human cyclic nucleotide pdes
10/10/2001EP1141325A1 Ikk3 kinase
10/10/2001EP1141288A2 Lymphocytic membrane proteins
10/10/2001EP1141279A2 Tissue repair protein involved in orofacial clefting and uses thereof
10/10/2001EP1141278A2 Therapeutic phosphodiesterase inhibitors
10/10/2001EP1141266A2 Expression vectors comprising multiple shear stress responsive elements (ssre) and a gene of interest and methods of use thereof
10/10/2001EP1141240A1 Use of cd40 engagement to alter t cell receptor usage
10/10/2001EP1141111A1 Gel compositions
10/10/2001EP1141015A1 Insulin-like growth factor (igf) i mutant variants
10/10/2001EP1141011A2 Compounds and methods to inhibit or augment an inflammatory response
10/10/2001EP1140989A1 Alpha(v) beta(6) integrin inhibitors
10/10/2001EP1140972A1 New 7-alpha, 17-alpha-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases
10/10/2001EP1140969A1 Connective tissue growth factor fragments and methods and uses thereof
10/10/2001EP1140966A1 Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof
10/10/2001EP1140964A2 Connective tissue growth factor fragments and methods and uses thereof
10/10/2001EP1140945A1 Fused 1,2,4-thiadiazine derivatives, their preparation and use
10/10/2001EP1140943A2 Substituted pyrroloindoles
10/10/2001EP1140939A1 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-alpha]pyrimidines, and related pharmaceutical compositions and methods
10/10/2001EP1140931A1 5ht1 antagonists for antidepressant therapy
10/10/2001EP1140924A1 Piperazine derivatives
10/10/2001EP1140914A1 Non-peptide nk1 receptors antagonists
10/10/2001EP1140912A1 Process for the preparation of an acetate salt of paroxetine or paroxetine analogues
10/10/2001EP1140911A1 Process for the preparation of an acetate salt of paroxetine or paroxetine analogues
10/10/2001EP1140900A2 Pyrazole compounds and uses thereof
10/10/2001EP1140895A2 Thiopyran compounds as inhibitors of mmp
10/10/2001EP1140891A1 1,4-diazacycloheptane compounds, process for their preparation, and their use as medicaments
10/10/2001EP1140860A1 Pyrimidine compounds
10/10/2001EP1140835A1 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
10/10/2001EP1140828A1 3-azabicyclo[3.1.0]hexane derivatives as opiate receptors ligands
10/10/2001EP1140784A2 Ion channel modulating agents
10/10/2001EP1140783A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
10/10/2001EP1140289A1 Method for prevention and treatment of cancer and other cell proliferative diseases with ultrasonic energy
10/10/2001EP1140202A1 Peptidic product, process and composition
10/10/2001EP1140199A1 Hyaluronate lyase used for promoting penetration in topical agents
10/10/2001EP1140194A2 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia
10/10/2001EP1140193A2 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
10/10/2001EP1140192A2 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
10/10/2001EP1140183A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
10/10/2001EP1140182A2 Use of a matrix metalloproteinase inhibitor together with an antineoplastic agent, optionally also together with radiation, in the treatment of neoplasia
10/10/2001EP1140180A2 Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
10/10/2001EP1140179A2 Use of a cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
10/10/2001EP1140178A2 Use of a matrix metallaproteinase inhibitor and radiation as a combined treatment of neoplasia
10/10/2001EP1140177A2 Use of an integrin antagonist and radiation in the treatment of neoplasia
10/10/2001EP1140175A2 Antibodies to truncated vegf-d and uses thereof
10/10/2001EP1140174A1 Agonists or antagonists of cutaneous t cell-attracting chemokine (ctack) or vasoactive intestinal contractor (vic) chemokines
10/10/2001EP1140173A2 Vascular endothelial cell growth factor antagonists and uses thereof
10/10/2001EP1140124A1 Use of unsaponifiable matters of vegetable oils for preparing a medicine
10/10/2001EP1140117A2 Aciclovir compositions containing dimethicone
10/10/2001EP1140113A2 Use of bisphosphonates for the prevention and treatment of infectious processes
10/10/2001EP1140112A1 Use of etherlysophospholipids as antiinflammatory agents
10/10/2001EP1140098A2 Tricyclic nitrogen heterocycles as pde iv inhibitors
10/10/2001EP1140091A2 Formulations comprising imiquimod or other immune response modifiers for treating mucosal consitions
10/10/2001EP1140083A1 Novel compounds
10/10/2001EP1140078A2 Benzimidazole vascular damaging agents
10/10/2001EP1140073A1 Combinations of farnesyl transferase inhibitors and irinotecan or camptothecin for treating cancer
10/10/2001EP1140072A1 Compounds and methods
10/10/2001EP1140071A1 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
10/10/2001EP1140069A1 COMPOUNDS WHICH AFFECT mRNA STABILITY AND USES THEREFOR
10/10/2001EP1140066A1 Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use
10/10/2001EP1140052A2 Sensitizing agents for the treatment of skin lesions
10/10/2001EP1140048A2 Methods for treating certain diseases using naaladase inhibitors
10/10/2001EP1140040A1 Spray-type cosmetic composition and matrix used in said composition for dermal administration
10/10/2001EP1140021A1 Improved formulation for topical non-invasive application in vivo
10/10/2001EP1140010A2 Substrate composition and method of use for sequestration of skin irritants
10/10/2001EP1140009A2 Absorbent article composition and method of use for sequestering skin irritants
10/10/2001EP1140006A1 Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis
10/10/2001EP1140003A1 Skin care composition containing cis-9, trans-11 linoleic acid
1 ... 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 ... 1065